Global drugmaker Merck reported Oct. 6 its COVID-19 antiviral treatment, Lagevrio, did not reduce hospitalizations and deaths in a trial sponsored by the University of Oxford, adding to other indicators that COVID-19 treatments are losing their strength.
Read the full post on Becker's Hospital Review - Healthcare News
